Ollin Biosciences
A clinical-stage biotech advancing therapies for vision-threatening diseases.
Healthcare
📍 Austin, TX
Founded 2023
Current Valuation
Private
PRIVATE
A clinical-stage biotech advancing therapies for vision-threatening diseases. Headquartered in Austin, TX. Raised $330M in Series B funding in June 2026 led by TCGX.
Company Profile
Last Round
Series B — $330M (Jun 2026) · Lead: TCGX
Fundraising Status
Series B · $330M · this month
privateTotal raised $330M1 disclosed rounds
Funding History
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Series B | $330M | Jun 2026 | TCGX | — |
Investors
TCGX · ARCH Venture Partners · a16z Bio+Health · Blackstone Multi-Asset Investing · Commodore Capital · CPP Investments · RA Capital Management · T. Rowe Price Investment Management · Mubadala Capital · Monograph Capital
HealthcareBiotechnologyRecently Funded
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.